TriSalus Life Sciences, Inc. (NASDAQ:TLSIW) Shares Shorted: Short Interest Down 47.7% in September

TriSalus Life Sciences, Inc. (NASDAQ:TLSIW) was the target of a large decrease in short interest during the month of September. As of September 30th, there was short interest totaling 9,356 shares, a decrease of 47.7% from the September 15th total of 17,898 shares. Based on an average daily volume of 2,596 shares, the short-interest ratio is presently 3.6 days.

TriSalus Life Sciences Stock Performance

NASDAQ:TLSIW traded down $0.08 during trading hours on Thursday, hitting $0.71. The company had a trading volume of 4,012 shares, compared to its average volume of 4,919. The stock has a 50-day moving average price of $0.91 and a 200 day moving average price of $0.85. TriSalus Life Sciences has a 52 week low of $0.44 and a 52 week high of $1.85.

Institutional Investors Weigh In On TriSalus Life Sciences

An institutional investor recently bought a new position in TriSalus Life Sciences stock. State Street Corp bought a new position in TriSalus Life Sciences, Inc. (NASDAQ:TLSIW) during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 610,963 shares of the company’s stock, valued at approximately $2,780,000.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences is an oncology company focused on developing and commercializing therapies and medical technologies for difficult-to-treat solid tumors, particularly liver and pancreatic cancers. The company combines interventional oncology, drug delivery and immunotherapy to address the tumor microenvironment and improve treatment delivery.

TriSalus’ technology platform includes Pressure-Enabled Drug Delivery (PEDD), a method designed to help administer therapies directly into tumors or their associated blood vessels.